Lessons from the Use of Monoclonal Antibodies to SARS-CoV-2 Spike Protein During the COVID-19 Pandemic.

Publication date: Dec 04, 2024

Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 Spike protein were deployed during the COVID-19 pandemic. While all of the clinically authorized mAbs were eventually defeated by SARS-CoV-2 variants, they were highly effective in preventing disease progression when given early in the course of the disease. The experience with mAbs to SARS-CoV-2 offers important lessons for the use of mAbs in future infectious disease emergencies, such as choosing mAbs that target conserved epitopes and designing cocktails to reduce the emergence of escape variants. Planning for future use must include the creation of infusion centers and the development of strategies to minimize the emergence of escape variants.

Concepts Keywords
Antibodies Antibodies
Cocktails Cov
Future Covid
Lessons Deployed
Pandemic Emergence
Escape
Future
Lessons
Mabs
Monoclonal
Pandemic
Sars
Spike
Targeting
Variants

Semantics

Type Source Name
disease MESH COVID-19 Pandemic
disease MESH disease progression
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH emergencies

Original Article

(Visited 3 times, 1 visits today)